Condition deep-dive · 10 min read

Peptic ulcer disease supplement protocol — what supports mucosal healing

Last reviewed: · Editorial team

Updated 2026-05-23 · Reviewed by SupplementScore editors · No sponsorships

Peptic ulcer disease (PUD) — open sores in the lining of the stomach (gastric ulcer) or upper small intestine (duodenal ulcer) — affects roughly 4 million people in the United States and an estimated 5–10% of adults worldwide over a lifetime. The cause is almost always either Helicobacter pylori infection (about 70% of gastric and 90% of duodenal ulcers) or NSAID use; the long-disproven "stress and spicy food" model still shapes how people self-treat. Proton pump inhibitors (PPIs) and H. pylori eradication antibiotics are the standard-of-care backbone. The supplement question is narrow: a small set of agents has real evidence for accelerating mucosal healing, improving H. pylori eradication rates as adjuncts, or relieving NSAID-induced damage. This page lays out what holds up in trials, the conditional add-ons, and the medication-interaction surface that matters.

Active bleeding, melena, hematemesis, or severe pain are medical emergencies — not supplement situations. Black tarry stools, vomiting blood (or coffee-ground material), syncope, or sudden severe abdominal pain with rigidity mean go to the emergency department now. A perforated ulcer is a surgical emergency. Untreated H. pylori is also a gastric cancer risk factor — supplements are never a substitute for endoscopy when alarm features are present (weight loss, dysphagia, persistent vomiting, age >55 with new dyspepsia, iron-deficiency anemia, family history of gastric cancer). Test, treat, then consider adjuncts.

The role of supplements in peptic ulcer disease

Three interventions dominate PUD outcomes: (1) stop the cause — NSAIDs, alcohol, and smoking; (2) eradicate H. pylori if present, with appropriate first-line triple or quadruple therapy; (3) acid suppression with PPIs for 4–8 weeks to allow healing. Modern PPI regimens heal >90% of duodenal ulcers in four weeks and >85% of gastric ulcers in eight weeks. Supplements sit one layer below this. The reasonable question is not "can I avoid the PPI?" but "can I speed mucosal healing, soften gastritis symptoms, raise eradication rates by 5–10 percentage points, or protect the mucosa when chronic NSAIDs are unavoidable?" The agents below have credible answers. Most of the supplement aisle does not.

Top supplements with strong evidence

Tier 1 evidence · The best non-prescription anti-H. pylori signal

Mastic gum (Pistacia lentiscus resin)

350–1,000 mg three times daily, on empty stomach, for 14 days

Mastic gum is the resin of the Greek Pistacia lentiscus tree and has direct bactericidal activity against H. pylori demonstrated in vitro at minimum inhibitory concentrations easily achievable in the gastric lumen (Huwez 1998, Paraschos 2007). In a 2010 RCT, 1 g/day for 14 days achieved a modest but real H. pylori clearance rate as monotherapy (~30%), and as a quadruple-therapy adjunct it has shown improved eradication and symptom relief in several small trials. It is not a stand-alone replacement for triple/quadruple therapy in confirmed infection — eradication rates with PPI + clarithromycin + amoxicillin still exceed 80% — but it is a reasonable adjunct, especially in clarithromycin-resistant regions. Tier 1 on the SupplementScore evidence scale for symptomatic dyspepsia and as an eradication adjunct.

Tier 1 evidence · Approved as a drug in Japan since 1994

Zinc-carnosine (polaprezinc)

75 mg twice daily (chelated zinc-L-carnosine)

Zinc-carnosine — sold internationally as a supplement but used in Japan as the prescription anti-ulcer drug polaprezinc — is the most clinically evidence-rich supplement for gastric mucosal repair. The Mahmood 2007 study and multiple Japanese RCTs show it stabilises the gastric mucosa, accelerates ulcer healing, and reduces NSAID-induced gastric injury (Watari 1986; Cho 1991). Mechanism: the chelate adheres to ulcer beds, slowly releasing zinc (a cofactor for mucosal proliferation) and carnosine (a free-radical scavenger) directly at the injured surface. In a 5-day NSAID challenge study, 75 mg twice daily significantly reduced indomethacin-induced gastric permeability. Tier 1 for mucosal-protective effects.

Tier 1 evidence · Mucosal coating without rebound acid

Deglycyrrhizinated licorice (DGL)

380–760 mg chewable, 20 minutes before meals, three times daily

Standard licorice (Glycyrrhiza glabra) raises blood pressure via mineralocorticoid effects; deglycyrrhizination removes the offending glycyrrhizin while preserving the flavonoid fraction. DGL stimulates mucin secretion, increases mucosal cell turnover, and demulcent-coats the gastric lining. Older head-to-head studies showed DGL produced ulcer-healing rates comparable to cimetidine (Morgan 1982; Larkworthy 1975). Modern evidence is mostly mechanistic and from small trials, but the safety profile is excellent and DGL remains a reasonable adjunct for symptomatic gastritis and ulcer healing — particularly for people who can't or won't stay on PPIs long-term. Use the deglycyrrhizinated form only; whole-licorice extracts can cause hypokalemia and hypertension.

Tier 1 evidence · Improves eradication rates and reduces side effects

Probiotics (Lactobacillus and Saccharomyces boulardii)

L. reuteri DSM 17648 at 2×10⁸ CFU twice daily during eradication, or S. boulardii 250 mg twice daily; continue 4 weeks

The Wang 2013 meta-analysis (10 RCTs) and the Szajewska 2015 meta-analysis (11 RCTs) both showed that adding probiotics to standard triple therapy increased H. pylori eradication rates by ~10 percentage points and reduced antibiotic-associated diarrhoea by roughly half. Specific strains with positive trials include L. reuteri, L. rhamnosus GG, S. boulardii, and L. casei Shirota. Mechanism: direct competition with H. pylori for gastric epithelial binding sites, production of antimicrobial bacteriocins, and gut barrier preservation through antibiotic-induced dysbiosis. Probiotics do not eradicate H. pylori on their own — they raise the success rate of antibiotic therapy and reduce side-effect dropout.

Tier 2 evidence · Specifically for H. pylori-positive patients

Sulforaphane / broccoli sprout extract

Equivalent of 70 g/day broccoli sprouts, or 30 mg/day standardised sulforaphane

Sulforaphane is the isothiocyanate generated from glucoraphanin in broccoli sprouts. In the Yanaka 2009 RCT, 70 g/day of broccoli sprouts for 8 weeks reduced H. pylori colonisation markers (urea breath test values, stool antigen) and lowered gastric mucosal inflammation in H. pylori-positive adults. It does not consistently achieve full eradication on its own, but as an adjunct it has bactericidal activity in vitro at concentrations achievable in the gastric lumen, and it upregulates Nrf2-driven cytoprotective enzymes in gastric mucosa — a plausible reason to combine it with PPI therapy in established gastritis. Useful in patients who decline or can't tolerate antibiotic eradication.

Tier 2 evidence · Repletes a near-universal deficit during chronic PPI use

Vitamin C (ascorbic acid)

250–500 mg/day with meals (slow-release or buffered if reflux-prone)

Gastric ascorbic acid concentrations are reduced in H. pylori-positive patients and during chronic PPI use (PPIs blunt gastric ascorbate by raising pH). The Sezikli 2009 RCT showed adding 500 mg vitamin C plus 200 IU vitamin E to standard triple therapy improved H. pylori eradication versus triple therapy alone. Vitamin C also supports mucosal collagen synthesis, which matters for connective-tissue repair during ulcer healing. Avoid very large doses (>1,000 mg) on an empty stomach — direct irritation can worsen dyspepsia.

Conditional / situational supplements

Conditional · Vitamin D3 (if 25(OH)D < 30 ng/mL)

Observational data link low 25-hydroxyvitamin D with higher H. pylori prevalence and slower mucosal healing, plausibly via cathelicidin-mediated antimicrobial immunity. Test 25(OH)D, replete to 30–50 ng/mL with vitamin D3 1,000–2,000 IU/day if deficient. Not a stand-alone PUD therapy — but correcting frank deficiency is reasonable given the immune-defence role and the high background prevalence of low D in PUD cohorts.

Conditional · Omega-3 (NSAID-dependent patients)

For people who genuinely cannot stop NSAIDs (rheumatologic disease, chronic pain syndromes), omega-3 fatty acids 2–3 g/day combined EPA+DHA can reduce some inflammatory drivers and have weak evidence for limiting NSAID gastropathy. They do not protect against NSAID ulcers on their own — co-prescribed PPI cover is still the standard of care for NSAID-dependent patients with prior ulcer history. Useful as a layered adjunct, not a substitute.

Conditional · L-glutamine (for atrophic gastritis or post-eradication healing)

L-glutamine is the preferred fuel substrate for rapidly dividing enterocytes and small-bowel mucosa. Animal data and small human trials suggest 5 g three times daily may accelerate gastric and duodenal mucosal repair, particularly post-eradication or in atrophic gastritis. Evidence is weaker than for the Tier 1 picks; reasonable conditional layer for patients with prolonged dyspepsia after successful H. pylori treatment.

Conditional · Curcumin (for H. pylori-positive gastritis where antibiotics are deferred)

Curcumin has in vitro activity against H. pylori and modest clinical evidence (Di Mario 2007) for symptom relief in non-ulcer dyspepsia. It does not produce reliable eradication on its own. Reasonable adjunct for symptomatic gastritis; use a bioavailable form (phytosome/Meriva, piperine-paired, or liposomal). Bleeding-risk caution if combined with anticoagulants.

What to skip

Medication considerations

Many people with PUD are on multiple medications. The interaction picture matters more than usual because absorption is altered by acid suppression and several of the eradication antibiotics carry their own interaction risk.

The lifestyle bedrock

The interventions that genuinely shift PUD outcomes sit upstream of any supplement: stop smoking (delays healing and increases recurrence), reduce or stop alcohol during active disease, avoid NSAIDs where possible, identify and eradicate H. pylori, complete the full PPI course. Stress and food choices are real symptom modulators but rarely the underlying cause — the mid-20th-century model that blamed "type A personality" and spicy diets was overturned when Warren and Marshall identified H. pylori as the etiologic agent (a discovery that won the 2005 Nobel Prize). The supplement layer augments the medical layer; it does not replace endoscopy when alarm features are present, and it does not replace antibiotics when H. pylori is confirmed. Anyone offering a pure-supplement protocol for an active bleeding ulcer is selling you something dangerous.

Practical layered start. (1) See a clinician — test for H. pylori (urea breath, stool antigen, or biopsy at endoscopy). If positive, complete the appropriate first-line eradication regimen. (2) Add probiotics (L. reuteri or S. boulardii) twice daily for the 14-day antibiotic course and continue 4 weeks. (3) Layer zinc-carnosine 75 mg twice daily for 8 weeks for mucosal repair. (4) For symptomatic dyspepsia, add mastic gum 1 g/day for 14 days or DGL 760 mg before meals. (5) Test 25(OH)D and replete if low. (6) If H. pylori-positive and antibiotics are deferred, consider sulforaphane from broccoli sprout extract. (7) Stop NSAIDs and smoking. (8) Confirm eradication by urea breath test or stool antigen 4 weeks after finishing antibiotics and 2 weeks off PPI.

Sources

Read more:

Supplement details

Related conditions